Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Gains from Investment Securities (2022 - 2025)

Cardio Diagnostics Holdings' Gains from Investment Securities history spans 4 years, with the latest figure at $6236.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 95.16% year-over-year to $6236.0; the TTM value through Sep 2025 reached $6236.0, down 95.16%, while the annual FY2024 figure was $119807.0, 39.06% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $6236.0 at Cardio Diagnostics Holdings, down from $6944.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 million in Q2 2023 and bottomed at $1012.0 in Q2 2024.
  • The 4-year median for Gains from Investment Securities is $127356.5 (2024), against an average of $906070.2.
  • The largest annual shift saw Gains from Investment Securities crashed 99.96% in 2024 before it surged 586.17% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $1.8 million in 2022, then plummeted by 95.1% to $86153.0 in 2023, then skyrocketed by 39.06% to $119807.0 in 2024, then plummeted by 94.79% to $6236.0 in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Gains from Investment Securities are $6236.0 (Q3 2025), $6944.0 (Q2 2025), and $2524.0 (Q1 2025).